Dianxiong Zou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dianxiong Zou has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Majeti N. V. Ravi Kumar
The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA
3 shared publications - Meenakshi Arora
The University of Alabama
3 shared publications Ahil N. Ganesh
Novartis Institutes for BioMedical Research, Cambridge, MA, United States
1 shared publication- Annette Bak
Advanced Drug Delivery, AstraZeneca R&D, Boston MA, USA
1 shared publication - Chandra Mohan
Department Biomedical Engineering, University of Houston, United States
1 shared publication Eric Gruff
E4 Consulting, Poway, CA, United States
1 shared publication
Latest Publications
- 19 August 2022
- Published by Elsevier
- p. 131-166
Nanoparticle-assisted oral delivery of small and large peptides
- 19 August 2022
- Published by Elsevier
- p. 131-166
Nanoparticle-assisted oral delivery of small and large peptides
- 19 August 2022
- Published by Elsevier
List of contributors
- Open Access
- 12 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (24) , eabb3900
A highly potent lymphatic system–targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus
Cyclosporine A (CsA) is a powerful immunosuppressant, but it is an ineffective stand-alone treatment for systemic lupus erythematosus (SLE) due to poor target tissue distribution and renal toxicity. We hypothesized that CD71 (transferrin receptor 1)–directed delivery of CsA to the lymphatic system would improve SLE outcomes in a murine model. We synthesized biodegradable, ligand-conjugated nanoparticles [P2Ns–gambogic acid (GA)] targeting CD71. GA conjugation substantially increased nanoparticle association with CD3+ or CD20+ lymphocytes and with intestinal lymphoid tissues. In orally dosed MRL-lpr mice, P2Ns-GA–encapsulated CsA increased lymphatic drug delivery 4- to 18-fold over the ligand-free formulation and a commercial CsA capsule, respectively. Improved lymphatic bioavailability of CsA was paralleled by normalization of anti–double-stranded DNA immunoglobulin G titer, plasma cytokines, and glomerulonephritis. Thus, this study demonstrates the translational potential of nanoparticles that enhance the targeting of lymphatic tissues, transforming CsA into a potent single therapeutic for SLE.
- 12 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (24) , eabb3900
Open AccessA highly potent lymphatic system–targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus
Cyclosporine A (CsA) is a powerful immunosuppressant, but it is an ineffective stand-alone treatment for systemic lupus erythematosus (SLE) due to poor target tissue distribution and renal toxicity. We hypothesized that CD71 (transferrin receptor 1)–directed delivery of CsA to the lymphatic system would improve SLE outcomes in a murine model. We synthesized biodegradable, ligand-conjugated nanoparticles [P2Ns–gambogic acid (GA)] targeting CD71. GA conjugation substantially increased nanoparticle association with CD3+ or CD20+ lymphocytes and with intestinal lymphoid tissues. In orally dosed MRL-lpr mice, P2Ns-GA–encapsulated CsA increased lymphatic drug delivery 4- to 18-fold over the ligand-free formulation and a commercial CsA capsule, respectively. Improved lymphatic bioavailability of CsA was paralleled by normalization of anti–double-stranded DNA immunoglobulin G titer, plasma cytokines, and glomerulonephritis. Thus, this study demonstrates the translational potential of nanoparticles that enhance the targeting of lymphatic tissues, transforming CsA into a potent single therapeutic for SLE.